Last 13 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.71 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.19 | 3.28 | 2.67 | 1.91 | 1.71 | 0.72 | 0.37 | 0.61 | 0.70 | 0.97 | 1.63 | — | — | — |
| — | +355.4% | +616.2% | +214.8% | +145.9% | -25.8% | -77.2% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.7% | -21.2% | -18.6% | -19.7% | -21.9% | -20.6% | -18.2% | -13.2% | -10.8% | -8.3% | -0.0% | -35.0% | -7.2% | -3.6% |
| — | -3.0% | -2.1% | -49.4% | -101.8% | -148.5% | -139870.8% | +62.4% | -50.7% | -128.7% | — | — | — | — | |
| ROA | -53.9% | -16.1% | -14.4% | -15.7% | -17.8% | -17.3% | -15.8% | -11.6% | -9.8% | -7.6% | -0.0% | -24.7% | -6.4% | -3.4% |
| — | +7.0% | +8.7% | -35.0% | -81.1% | -125.9% | -137218.3% | +52.8% | -53.2% | -127.9% | — | — | — | — | |
| ROIC | -80.8% | -16.3% | -18.6% | -22.7% | -22.4% | -21.4% | -20.2% | -16.0% | -13.9% | -14.0% | -0.0% | -40.6% | -12.0% | — |
| — | +23.9% | +8.1% | -41.9% | -61.2% | -53.5% | -78443.2% | +60.6% | -15.3% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.20 | 0.17 | 0.12 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.18 | 0.14 | 0.03 |
| — | +521.0% | +457.2% | +304.3% | +9.6% | +7.1% | +3.1% | -83.3% | -78.5% | -0.2% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.75 | 9.06 | 8.15 | 7.75 | 5.16 | 5.39 | 7.44 | 8.61 | 10.50 | 14.86 | 17.17 | 3.05 | 4.71 | 17.17 |
| — | +68.2% | +9.5% | -9.9% | -50.8% | -63.7% | -56.7% | +181.8% | +123.1% | -13.5% | — | — | — | — | |
| Quick Ratio | 7.75 | 9.06 | 8.15 | 7.75 | 5.16 | 5.39 | 7.44 | 8.61 | 10.50 | 14.86 | 17.17 | 3.05 | 4.71 | 17.17 |
| — | +68.2% | +9.5% | -9.9% | -50.8% | -63.7% | -56.7% | +181.8% | +123.1% | -13.5% | — | — | — | — | |
| Interest Coverage | -328.87 | -58.66 | -58.56 | -84.14 | -5254.29 | -3004.79 | -1784.40 | -1387.48 | -1158.44 | -737.54 | -0.64 | -454.83 | -308.30 | -283.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KYTX stock.
Kyverna Therapeutics, Inc.'s current P/E is -1.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kyverna Therapeutics, Inc.'s business trajectory between earnings reports.